2.13BMarket Cap-5076P/E (TTM)
13.479High12.150Low7.04MVolume12.320Open12.145Pre Close91.11MTurnover4.90%Turnover RatioLossP/E (Static)160.09MShares23.86052wk High-4.93P/B1.91BFloat Cap3.53252wk Low--Dividend TTM143.45MShs Float331.680Historical High--Div YieldTTM10.94%Amplitude3.532Historical Low12.950Avg Price1Lot Size
Novavax Stock Forum
Larger Image: tradingview.com...
$Novavax (NVAX.US)$
The company said its 2024-2025 formula COVID-19 vaccine is in stock at major pharmacy retailers nationwide.
* Partnering with Sanofi and Serum Institute providing significant revenue opportunities in the form of royalties and markey expansion
* Expense reduction looks big, so I would expect at least break even, or profit making. Looking forward to FY results
* Pipeline broadening - pneumococcal, RSV and H5N1 mentioned. Promosing data showing superiority for pneumococcal expected
Larger Image: tradingview.com...
$Novavax (NVAX.US)$
Novavax 2024-2025 Formula COVID-19 Vaccine Now Authorized and Recommended for Use in the U.S.
Novavax has received Emergency Use Authorization (EUA) from the FDA for its 2024-2025 Formula COVID-19 Vaccine(NVX-CoV2705) for individuals aged 12 and older. The vaccine is included in the CDC's recommendations and will be available in pre-filled syringes at thousands of locations across the U.S. Novavax's vaccine is the only protein-based option available in the U.S. for COVID...
No comment yet